Pyroglutamate-modified amyloid- (pE-A) is a highly neurotoxic amyloid- (A) isoform and is enriched in the brains of individuals with Alzheimer disease compared with healthy aged controls. Pyroglutamate formation increases the rate of A oligomerization and alters the interactions of A with Cu 2؉ and lipids; however, a link between these properties and the toxicity of pE-A peptides has not been established. We report here that A3pE-42 has an enhanced capacity to cause lipid peroxidation in primary cortical mouse neurons compared with the fulllength isoform (A(1-42)). In contrast, A(1-42) caused a significant elevation in cytosolic reactive oxygen species, whereas A3pE-42 did not. We also report that A3pE-42 preferentially associates with neuronal membranes and triggers Ca 2؉ influx that can be partially blocked by the N-methyl-D-aspartate receptor antagonist MK-801. A3pE-42 further caused a loss of plasma membrane integrity and remained bound to neurons at significantly higher levels than A(1-42) over extended incubations. Pyroglutamate formation was additionally found to increase the relative efficiency of A-dityrosine oligomer formation mediated by copper-redox cycling.A 3 peptides are found in every human brain; however, the concentration and composition of A peptide isoforms are distinctly different in healthy individuals and people with AD (1-3). Amino-truncated A peptides are abundant in the AD brain (4, 5) and increase in prevalence with disease progression (6). The process of A amino-truncation can occur via the actions of aminopeptidases on full-length A peptides (7, 8), via altered cleavage of amyloid precursor protein in the generation of A (9 -11), and potentially by A-copper-redox cycling reactions (12). As a consequence, aminotruncation can expose glutamate residues (positions 3 and 11 of A) to cyclization by the action of glutaminyl cyclase (QC), forming the highly amyloidogenic pyroglutamate-A (pE-A) peptides A3pE-40, A3pE-42, A11pE-40, and A11pE-42 (7, 13).Pyroglutamate formation significantly increases the hydrophobicity of A, causing the peptide to aggregate more rapidly and form oligomers at lower concentration thresholds (5, 14, 15). pE-A peptides also demonstrate increased -sheet (aggregate structure) stability (16, 17), differences in fibril ultrastructure (18,19), and altered interactions with copper ions (20, 21) and synthetic lipid membranes (22, 23). Notably, trace quantities of A3pE-42 have been observed to dramatically enhance the aggregation and neurotoxicity of A(1-42) (24), prompting descriptions of pE-A as "prionlike." Still, it remains unclear as to the cytotoxic potency of pE-A peptides compared with their full-length A counterparts. Some studies have demonstrated pE-A peptides to have enhanced toxicity (24 -26), although others have reported no difference in toxicity between the isoforms (27-30). Methodological differences may account somewhat for variability in the relative toxicities reported (Table 1), yet molecular mechanisms to explain...